Development and assessment of a novel real-time PCR assay for quantitation of hepatitis D virus RNA to study viral kinetics in chronic hepatitis D.

Abstract:

:Hepatitis delta virus (HDV) infection is a usually severe type of viral hepatitis associated with increased mortality and rapid evolution to cirrhosis. Currently, treatment is limited to extended interferon administration and measurement of HDV RNA blood levels is essential to judge the response. The aim of this study was to develop a highly sensitive and reproducible real-time reverse transcriptase-polymerase chain reaction (real-time RT-PCR) for the quantitation of circulating HDV RNA of all clades (1-8), and assess its usefulness in the follow-up of patients. The amplification was combined with molecular beacon technology using the LightCycler 2.0 system. The assay was specific and showed linearity over a wide range from 13 to 13 × 10(10) copies/mL. The 95% detection limit was 43.2 copies/mL. Intra-assay reproducibility, as expressed by the coefficient of variation, ranged from 1.84 to 18.61%, whereas the corresponding estimates for the inter-assay variability ranged from 0.57 to 10.18%. Finally, the dynamic profiles of six patients regarding virological (HDV RNA, HBV DNA), biochemical and serological data were constructed. We were able to observe that most patients who were treated with an interferon-based regime showed a significant reduction in delta viremia. In conclusion, our real-time RT-PCR for HDV RNA quantification combines high sensitivity and reproducibility in a high dynamic range, can provide important information for patient management and can be a useful tool for monitoring the response to antiviral therapies.

journal_name

J Viral Hepat

authors

Katsoulidou A,Manesis E,Rokka C,Issaris C,Pagoni A,Sypsa V,Hatzakis A

doi

10.1111/jvh.12000

subject

Has Abstract

pub_date

2013-04-01 00:00:00

pages

256-62

issue

4

eissn

1352-0504

issn

1365-2893

journal_volume

20

pub_type

杂志文章
  • Frequency and clinical outcomes of flares related to nucleos(t)ide analogue therapy in patients with chronic hepatitis B.

    abstract::Flares in chronic hepatitis B are often detrimental but sometimes lead to sustained immune control and disease remission. The aim of this study was to estimate the frequency of hepatitis flares which occur during and/or after cessation of nucleos(t)ide analogue (NA) therapy, and to assess their outcomes. In a single c...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2011.01448.x

    authors: Zhang NP,Reijnders JG,Perquin M,Hansen BE,Janssen HL

    更新日期:2011-07-01 00:00:00

  • Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: A multicentre experience.

    abstract::Limited data are available on direct-acting antivirals for treating hepatitis C virus (HCV) infection in patients with severe renal impairment. The aim of this study was to evaluate the effectiveness and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) ± dasabuvir (DSV) ± ribavirin (RBV) in patients with stage ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,多中心研究

    doi:10.1111/jvh.12664

    authors: Muñoz-Gómez R,Rincón D,Ahumada A,Hernández E,Devesa MJ,Izquierdo S,Ortiz M,Hernández-Albujar A,Fernández-Rodríguez C,Calvo M,González R,Lozano M,Castellano G,Fernández-Vázquez I

    更新日期:2017-06-01 00:00:00

  • Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin*.

    abstract::In previous hepatitis C virus (HCV) treatment studies, Black patients not only had a lower sustained viral response (SVR) rate to interferon and ribavirin (RBV) than non-Black patients but also a higher frequency of HCV genotype 1 (GT-1) infection. The aim of this community-based study was to determine whether Black p...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1365-2893.2005.00682.x

    authors: Bräu N,Bini EJ,Currie S,Shen H,Schmidt WN,King PD,Ho SB,Cheung RC,Hu KQ,Anand BS,Simon FR,Aytaman A,Johnson DP,Awad JA,Ahmad J,Mendenhall CL,Pedrosa MC,Moseley RH,Hagedorn CH,Waters B,Chang KM,Morgan TR,Rossi

    更新日期:2006-04-01 00:00:00

  • HBsAg plasma level kinetics: a new role for an old marker as a therapy response predictor in vertically infected children on combination therapy.

    abstract::We aimed to investigate the ability of HBsAg plasma level kinetics to predict therapy response by studying 23 children with infancy-acquired chronic hepatitis B (CHB) during combination sequential therapy with lead-in lamivudine (LAM) and add-on interferon-α (IFN-α) [5 responders (R = anti-HBs seroconversion) and 18 n...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12316

    authors: Carey I,Bruce M,Horner M,Zen Y,D'Antiga L,Bansal S,Vergani D,Mieli-Vergani G

    更新日期:2015-04-01 00:00:00

  • Hepatitis C is more severe in drug users with human immunodeficiency virus infection.

    abstract::Drug users with chronic hepatitis C virus (HCV) infection are frequently co-infected with human immunodeficiency virus-1 (HIV-1), but it is still not clear whether HIV-1 worsens the natural history of hepatitis C. To investigate this, we conducted a multicentre observational study in 163 drug addicts with histological...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1046/j.1365-2893.2000.00230.x

    authors: Romeo R,Rumi MG,Donato MF,Cargnel MA,Viganò P,Mondelli M,Cesana B,Colombo M

    更新日期:2000-07-01 00:00:00

  • Morbidity and mortality of recurrent hepatitis C infection after orthotopic liver transplantation.

    abstract::Through molecular virological testing it is now clear that HCV reinfection of the allograft is virtually universal in liver transplant recipients. Although histopathological recurrence of hepatitis C occurs in the majority of patients, it is absent in a substantial minority. To date, no prognostic factors, other than ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2893.1997.tb00172.x

    authors: Vierling JM,Villamil FG,Rojter SE,Camacho KB,Goldman DE

    更新日期:1997-01-01 00:00:00

  • Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b.

    abstract::We compared sustained virological response (SVR) in chronic hepatitis C patients with severe fibrosis treated with pegylated interferon (Peg-IFN) alpha-2b 1.5 microg/kg/week or 0.75 microg/kg/week in combination with ribavirin 800 mg/day for 48 weeks. This was a multicentre randomized controlled study. SVR was observe...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2893.2006.00768.x

    authors: Abergel A,Hezode C,Leroy V,Barange K,Bronowicki JP,Tran A,Alric L,Castera L,Bernard PH,Henquell C,Lafeuille H,Ughetto S,Darcha C,Chevallier M,Martineau N,Dubost S,Randl K,Dhumeaux D,Bommelaer G,Bonny C,French mult

    更新日期:2006-12-01 00:00:00

  • Watchful waiting: role of disease progression on uncertainty and depressive symptoms in patients with chronic hepatitis C.

    abstract:BACKGROUND AND AIMS:New therapies for HCV are rapidly emerging and providers are advising select patients to defer treatment and elect 'watchful waiting'. During the watchful waiting period, patients have been shown to have high rates of illness uncertainty and depression. We sought to answer the question of whether re...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12207

    authors: Colagreco JP,Bailey DE,Fitzpatrick JJ,Musil CM,Afdhal NH,Lai M

    更新日期:2014-10-01 00:00:00

  • Dual effects of hepatitis C virus Core protein on the transcription of cyclin-dependent kinase inhibitor p21 gene.

    abstract::Transcription of p21 was activated in hepatitis C virus (HCV) Core-expressing HepG2 cells where its upstream p53 was stabilized. However, this effect was not absolutely required for the activation of p21 by Core, as demonstrated in Hep3B cells. In addition, an opposite effect on the transcription of p21 was observed i...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1046/j.1365-2893.2003.00434.x

    authors: Kwun HJ,Jang KL

    更新日期:2003-07-01 00:00:00

  • Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance.

    abstract::Liver damage may result from multiple factors in HIV-infected patients. The availability of reliable noninvasive tools to measure liver fibrosis has permitted the screening of large patient populations. Cross-sectional study of all consecutive HIV outpatients who underwent examination by transient elastometry (FibroSc...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2009.01261.x

    authors: Blanco F,Barreiro P,Ryan P,Vispo E,Martín-Carbonero L,Tuma P,Labarga P,Medrano J,González-Lahoz J,Soriano V

    更新日期:2011-01-01 00:00:00

  • The role of the hepatitis viruses in cholangiocarcinoma.

    abstract::Cholangiocarcinoma is the second most common liver cancer in the world. The aetiology of the disease is diverse incorporating a variety of conditions leading to biliary stasis, biliary and liver inflammation, but a large number of cases still occur in the absence of established risk factors. Its incidence and mortalit...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1111/jvh.12093

    authors: Ralphs S,Khan SA

    更新日期:2013-05-01 00:00:00

  • Semiquantitative assessment of IgM antibody to hepatitis B core antigen and prediction of the severity of chronic hepatitis B.

    abstract::Controversial results have been reported concerning the correlation between serum levels of IgM antibodies to hepatitis B core antigen (IgM HBcAb) and the histological activity of chronic hepatitis B. In this study, paired serum samples and liver biopsies were collected from 200 consecutive chronic hepatitis B patient...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1046/j.1365-2893.1999.00171.x

    authors: Colloredo G,Bellati G,Sonzogni A,Zavaglia C,Fracassetti O,Leandro G,Ghislandi R,Minola E,Ideo G

    更新日期:1999-11-01 00:00:00

  • Entecavir and tenofovir on renal function in patients with hepatitis B virus-related hepatocellular carcinoma.

    abstract::The use of tenofovir disoproxil fumarate (TDF) is associated with a risk of renal dysfunction. We investigated whether TDF is associated with the deterioration of renal function in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) requiring frequent computed tomography (CT) evaluations and t...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13313

    authors: Jeon MY,Lee JS,Lee HW,Kim BK,Park JY,Kim DY,Han KH,Ahn SH,Kim SU

    更新日期:2020-09-01 00:00:00

  • Controlled release recombinant human interferon-α2b for treating patients with chronic hepatitis C genotype 1: a phase 2a clinical trial.

    abstract::Better convenience and tolerability and sustained therapeutic concentrations might improve interferon (IFN) treatment for chronic hepatitis C virus (HCV) infection. In an open-label, randomized study, controlled release free (chemically unmodified) recombinant human IFN-α(2b) in poly(ether-ester) microspheres (CR-rhIF...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1365-2893.2010.01298.x

    authors: Dzyublyk I,Yegorova T,Moroz L,Popovych O,Zaytsev I,Miroshnichenko V,Kromminga A,Wilkes MM,van Hoogdalem EJ,Humphries JE

    更新日期:2011-04-01 00:00:00

  • Do antiviral CD8+ T cells select hepatitis C virus escape mutants? Analysis in diverse epitopes targeted by human intrahepatic CD8+ T lymphocytes.

    abstract::Hepatitis C virus (HCV) is a variable RNA virus that can readily establish persistent infection. Cellular immune responses are important in the early control of the virus. Evidence from animal models suggests that mutation in epitopes recognized by CD8+ T lymphocytes may play an important role in the establishment of ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2005.00676.x

    authors: Komatsu H,Lauer G,Pybus OG,Ouchi K,Wong D,Ward S,Walker B,Klenerman P

    更新日期:2006-02-01 00:00:00

  • Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin.

    abstract::Sustained virologic response (SVR) is the standard measure for evaluating response to therapy in patients with chronic hepatitis C (CHC). The aim of this study was to prospectively assess the durability of SVR in the pivotal studies of peginterferon (PEG-IFN) α-2b or IFN α-2b. We conducted two phase 3b long-term follo...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/jvh.12074

    authors: Manns MP,Pockros PJ,Norkrans G,Smith CI,Morgan TR,Häussinger D,Shiffman ML,Hadziyannis SJ,Schmidt WN,Jacobson IM,Bárcena R,Schiff ER,Shaikh OS,Bacon B,Marcellin P,Deng W,Esteban-Mur R,Poynard T,Pedicone LD,Brass CA

    更新日期:2013-08-01 00:00:00

  • T-helper cells and liver fibrosis in hepatitis C virus-monoinfected patients.

    abstract::Limited data suggest that low T-helper cell levels may be observed in hepatitis C virus (HCV) monoinfected patients with decompensated liver disease. We sought to determine the distribution and relationship of T-helper cells (CD4) to liver fibrosis in HCV-monoinfected patients before and during pegylated interferon (P...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2009.01173.x

    authors: Rashkin S,Rouster S,Goodman ZD,Sherman KE

    更新日期:2010-03-01 00:00:00

  • A randomized trial to assess the efficacy of interferon-alpha daily in combination with ribavirin in the treatment of naïve patients with chronic hepatitis C.

    abstract::A randomized trial was conducted to assess the efficacy of interferon-alpha (IFN) daily in combination with ribavirin in 301 naïve patients with chronic hepatitis C (CHC). Patients were randomized to receive ribavirin 1.2 g daily (QD) for 48 weeks with either IFN 5 MU (thrice weekly) TIW for 8 weeks followed by IFN 3 ...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2893.2003.00439.x

    authors: Tassopoulos NC,Ketikoglou I,Tsantoulas D,Raptopoulou M,Hatzis G,Vafiadis I,Sidiropoulos L,Kanatakis S,Anagnostopoulos G,Sypsa V,Hatzakis A,Hellenic Viral Hepatitis Research Network.

    更新日期:2003-09-01 00:00:00

  • Changes in characteristics of hepatitis C patients seen in a liver centre in the United States during the last decade.

    abstract::With the approval of 2 direct-acting antivirals (DAAs) in 2011 and anticipation of interferon (IFN)-free regimens, more hepatitis C virus (HCV) chronically infected patients are now seeking treatment. To describe the characteristics of newly referred HCV patients in 2011-2012 (Era-2) and compare them to those seen in ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12343

    authors: Talaat N,Yapali S,Fontana RJ,Conjeevaram HS,Lok AS

    更新日期:2015-05-01 00:00:00

  • Prevention of hepatitis C in Italy: lessons from surveillance of type-specific acute viral hepatitis. SEIEVA collaborating Group.

    abstract::Using data from the surveillance system for type-specific acute viral hepatitis, the temporal incidence trend of non-A, non-B acute hepatitis and risk factors for acute hepatitis C have been evaluated in Italy. The association between hepatitis C and the potential risk factors (odds ratios, OR) was estimated using hep...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1046/j.1365-2893.2000.00179.x

    authors: Mele A,Tosti ME,Marzolini A,Moiraghi A,Ragni P,Gallo G,Balocchini E,Santonastasi F,Stroffolini T

    更新日期:2000-01-01 00:00:00

  • Efficacy of lamivudine re-treatment for relapsed patients after an initial lamivudine therapy in HBeAg-positive chronic hepatitis B.

    abstract::The efficacy of lamivudine re-treatment in chronic hepatitis B (CHB) patients who relapse after HBeAg seroconversion with lamivudine has not been investigated. The aim of this study was to evaluate the efficacy of lamivudine re-treatment in relapsed patients. Among 192 patients who had achieved HBeAg seroconversion wi...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1365-2893.2005.00606.x

    authors: Shin JW,Park NH,Park JH,Park JH,Jeong ID,Bang SJ,Joo KR,Kim DH

    更新日期:2005-07-01 00:00:00

  • The expression of hepatitis B virus polymerase in hepatocytes during chronic HBV infection.

    abstract::A recombinant protein corresponding to part of the amino-terminal domain of hepatitis B virus (HBV) polymerase was expressed in Escherichia coli. Antisera raised against this protein stained hepatocytes, from human liver biopsies, predominantly in the nucleus but some cytoplasmic staining was also observed. No stainin...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.1996.tb00083.x

    authors: McGarvey MJ,Goldin RD,Karayiannis P,Thomas HC

    更新日期:1996-03-01 00:00:00

  • Anti-envelope antibody responses in highly exposed seronegative individuals may be associated with protection from HCV infection.

    abstract::In rare cases, individuals with a history of long-term injecting drug use remain seronegative and aviraemic, despite prolonged and likely repeated exposure to Hepatitis C virus (HCV) through high-risk behaviour. We describe anti-HCV Envelope (E) antibody responses in a prospective cohort of carefully defined highly ex...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13339

    authors: Mina M,Underwood A,Eltahla A,Wu BR,Walker MR,Bull RA,Lloyd AR

    更新日期:2020-10-01 00:00:00

  • Transmission of hepatitis C virus to infants of human immunodeficiency virus-negative intravenous drug-using mothers: rate of infection and assessment of risk factors for transmission.

    abstract::The risk of perinatal transmission of hepatitis C virus (HCV) from a cohort of 95 human immunodeficiency virus (HIV)-negative intravenous drug users (IVDU) is described, 89 of whom were positive for antibodies to HCV (anti-HCV). Infection, defined as the presence of HCV RNA in a serum sample collected from an infant a...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1046/j.1365-2893.1997.00073.x

    authors: Spencer JD,Latt N,Beeby PJ,Collins E,Saunders JB,McCaughan GW,Cossart YE

    更新日期:1997-01-01 00:00:00

  • Prevalence of hepatitis viruses in an anti-human immunodeficiency virus-positive population from Argentina. A multicentre study.

    abstract::The objectives of this study were to investigate the prevalence of infections with hepatotrophic viruses in an anti-human immunodeficiency virus (HIV)-positive population from Buenos Aires and to compare it among the main risk groups for HIV infection. Four hundred and eighty-four consecutive patients attending the HI...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,多中心研究

    doi:10.1046/j.1365-2893.1999.t01-1-6120135.x

    authors: Fainboim H,González J,Fassio E,Martínez A,Otegui L,Eposto M,Cahn P,Marino R,Landeira G,Suaya G,Gancedo E,Castro R,Brajterman L,Laplumé H

    更新日期:1999-01-01 00:00:00

  • Hepatitis delta virus propagation enabled by hepatitis C virus-Scientifically intriguing, but is it relevant to clinical practice?

    abstract::In vitro cell culture experiments and animal models have demonstrated that hepatitis delta virus (HDV) can theoretically propagate being enveloped by human pathogenic viruses other than hepatitis B virus (HBV), namely hepatitis C virus (HCV) and dengue virus. However, the clinical relevance of these findings and wheth...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13385

    authors: Pflüger LS,Schulze Zur Wiesch J,Polywka S,Lütgehetmann M

    更新日期:2021-01-01 00:00:00

  • Oxidative burst response of neutrophils primed with PreS1 antigen of hepatitis B virus in patients with chronic hepatitis B and convalescents.

    abstract::The pathogenesis of liver damage in the course of hepatitis B virus (HBV) infection depends on the host's specific and non-specific immune response to various viral antigens. The role of polymorphonuclear neutrophils (PMN) in the natural immune reaction and during secondary microbial infections is well documented. Inc...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.1996.tb00101.x

    authors: Sułowska Z,Pietruszynski R,Dworniak D,Tchórzewski H,Sidorkiewicz M

    更新日期:1996-11-01 00:00:00

  • In vivo infectivity of liver extracts after resolution of hepadnaviral infection following therapy associating DNA vaccine and cytokine genes.

    abstract::DNA-based vaccination appears of promise for chronic hepatitis B immunotherapy, although there is an urgent need to increase its efficacy. In this preclinical study, we evaluated the therapeutic benefit of cytokine (IL-2, IFN-γ) genes co-delivery with DNA vaccine targeting hepadnaviral proteins in the chronic duck hep...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12023

    authors: Saade F,Buronfosse T,Guerret S,Pradat P,Chevallier M,Zoulim F,Jamard C,Cova L

    更新日期:2013-04-01 00:00:00

  • Thymosin-alpha 1 plus interferon-alpha for naive patients with chronic hepatitis C: results of a randomized controlled pilot trial.

    abstract::In this pilot study, we evaluated the efficacy of interferon-alpha (IFN) plus Thymosin-alpha 1 (TA1) to that of IFN alone in naive patients with chronic hepatitis C. Twenty-two patients were randomized to receive interferon-alpha 2b (3 million units three times a week) plus thymosin-alpha l (900 microg/m2 body surface...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1046/j.1365-2893.2003.00470.x

    authors: Andreone P,Gramenzi A,Cursaro C,Felline F,Loggi E,D'Errico A,Spinosa M,Lorenzini S,Biselli M,Bernardi M

    更新日期:2004-01-01 00:00:00

  • Long-term efficacy of entecavir therapy in chronic hepatitis B patients with antiviral resistance to lamivudine and adefovir.

    abstract::No studies have reported the long-term effects of entecavir switching in patients with multidrug resistance who developed resistance after lamivudine/adefovir sequential therapy. We evaluated the efficacy of 96 weeks of entecavir therapy in patients with resistance to lamivudine/adefovir sequential therapy. In total, ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2011.01461.x

    authors: Kwak MS,Choi JW,Lee JS,Kim KA,Suh JH,Cho YS,Won SY,Park BK,Lee CK

    更新日期:2011-10-01 00:00:00